An interventional study of placebo tea and Salvia miltiorrhiza herbal tea in Eye and Myopia, sponsored by Chung Shan Medical University. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 36 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Chung Shan Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Myopia with a site in Taiwan — 6 open to participants now, 8 under way, none of them phase 3. Myopia · Taiwan.
Among the 40 studies in Myopia with a site in Taiwan, this one is the 26th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2021, is one of 23 with no phase, and was the 40th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →6 of the 40 studies in Myopia with a site in Taiwan are open now. Recruiting first, the newest first:
Hungkuang University · Sites in Taiwan
Ages 15–22 · Healthy volunteers
Kubota Vision Inc. · Sites in Taiwan
Ages 6–13 · Healthy volunteers
Essilor-Polylite Taiwan Co., Ltd. · Sites in Taiwan
Ages 6–12 · Healthy volunteers
Buddhist Tzu Chi General Hospital · Sites in Taiwan
Ages 8–23
National Taiwan University Hospital · Sites in Taiwan
Ages 6–10
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 20 Years to 36 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 65 across the 31 interventional studies, 100 across the 9 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 40 have an industry lead sponsor. The 10 most frequent:
Chung Shan Medical University is the lead sponsor of 126 studies on the registry; 25 are open to participants now.
Chung Shan Medical University has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
3 of the studies in Myopia with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579287Sunhawk Vision Biotech, Inc.A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | 2026-12 |
| NCT07345416Menicon Co., Ltd.A Clinical Trial Assessing the Efficacy and Safety of ST-1 Silicone Hydrogel Daily Disposable Soft Contact Lenses Compared to Miru 1day UpSide | 2026-12-31 |
| NCT07107646National Taiwan University HospitalExploring Perceptual Learning in Blurred Gabor Discrimination for Low-Myopic Children | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Myopia with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether Salvia miltiorrhiza tea can improve visual function and reduce visual discomfort in adults.
The main questions it aims to answer are:
Does Danshen tea improve visual function outcomes compared to placebo? Does Danshen tea reduce symptoms of visual discomfort?
Researchers will compare Danshen tea to a placebo (a similar-looking and tasting beverage without active ingredients) to evaluate its effectiveness.
Participants will:
Consume Danshen tea or a placebo twice daily for 42 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: placebo tea
Dietary Supplement: Salvia miltiorrhiza herbal tea
Participants in the intervention group will consume placebo tea twice daily for 42 days. The tea will be prepared using tea bags, each containing 2.5 ± 0.5 g, brewed with 300 ± 50 mL of warm water.
Participants in the intervention group will consume Salvia miltiorrhiza tea twice daily for 42 days. The tea will be prepared using tea bags, each containing 2.5 ± 0.5 g, brewed with 300 ± 50 mL of warm water.
Binocular Accommodative Facility Measured Using ±2.00 D Flipper Lenses (cycles per minute, cpm)
Binocular accommodative facility (BAF) will be assessed using the standard BAF test with ±2.00 diopter flipper lenses while participants view a near target at 40 cm. One complete accommodative cycle is defined as successfully clearing the target through both the +2.00 D and -2.00 D lenses. The number of complete cycles achieved within one minute will be recorded and expressed as cycles per minute (cpm).
Time frame: Baseline, Day 21, and Day 42
Near Point of Convergence Measured Using a Royal Air Force (RAF) Ruler (centimeters, cm)
Near point of convergence (NPC) will be assessed using the standard NPC test with a Royal Air Force (RAF) ruler while participants fixate on a near target moved along the midline toward the eyes. The NPC break point is defined as the distance at which binocular single vision is lost, and the NPC recovery point is defined as the distance at which binocular single vision is regained as the target moves away. Both measurements will be recorded as the distance from the bridge of the nose to the target and expressed in centimeters (cm).
Time frame: Baseline, Day 21, and Day 42
Amplitude of Accommodation Measured Using a Royal Air Force (RAF) Ruler (diopters, D)
Amplitude of accommodation (AA) will be assessed using the standard push-up method with a Royal Air Force (RAF) ruler while participants fixate on a near target. The target will be moved gradually toward the participant's eye until sustained blur is first reported. The near point of accommodation will be measured in centimeters (cm) and converted into diopters (D) using the reciprocal of the viewing distance in meters. The calculated accommodative amplitude will be recorded and expressed in diopters (D).
Time frame: Baseline, Day 21, and Day 42
Macular Pigment Optical Density Measured Using the MPS II or MPS 9000 (Hertz, Hz)
Macular pigment optical density (MPOD) will be assessed using heterochromatic flicker photometry (HFP) with the MPS II or MPS 9000 device. Participants will respond to a flickering visual stimulus according to the device's standard testing procedure. MPOD will be determined from the HFP measurements and recorded as an optical density value.
Time frame: Baseline, Day 21, and Day 42
Schirmer's Test Measured Using Standardized Schirmer Strips (millimeters, mm)
Tear production will be assessed using the Schirmer's test with standardized Schirmer filter paper strips placed in the lower conjunctival fornix. Participants will keep their eyes closed during the 5-minute measurement period. The length of the filter paper wetted by tears will be measured after 5 minutes and recorded in millimeters (mm), with greater wetting lengths indicating higher tear production.
Time frame: Baseline, Day 21, and Day 42
Tear Break-Up Time Measured Using Fluorescein Staining and a Slit Lamp (seconds, s)
Tear break-up time (TBUT) will be assessed using the standard fluorescein tear break-up time test with fluorescein staining and a slit-lamp biomicroscope equipped with cobalt blue illumination. Participants will be instructed to blink normally and then keep their eyes open without blinking. The time interval between the last complete blink and the first appearance of a dry spot in the tear film will be measured and recorded in seconds (s). Longer TBUT values indicate greater tear film stability.
Time frame: Baseline, Day 21, and Day 42
Tear Meniscus Height Measured Using a Slit-Lamp Biomicroscope (millimeters, mm)
Tear meniscus height (TMH) will be assessed using a slit-lamp biomicroscope. The vertical height of the lower tear meniscus at the central lower eyelid will be measured as the distance between the lower eyelid margin and the upper boundary of the tear meniscus. The measured height will be recorded and expressed in millimeters (mm).
Time frame: Baseline, Day 21, and Day 42
Dry Eye Symptoms Measured Using the Dry Eye Questionnaire 5 (DEQ-5) (total score)
Dry eye symptoms will be assessed using the validated 5-item Dry Eye Questionnaire (DEQ-5), which evaluates the frequency and intensity of dry eye symptoms, including ocular discomfort and dryness, as well as the frequency of watery eyes. The total DEQ-5 score ranges from 0 to 22 points, with higher scores indicating more severe dry eye symptoms. The total score will be calculated and recorded for each participant.
Time frame: Baseline, Day 21, and Day 42
Ran from Feb 2021 to primary completion in Sep 2021, 7 months.
Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's 7 months is below that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chung Shan Medical University →